Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers. The company is also developing Axalimogene filolisbac for the treatment of anal cancer; ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is designed to target the prostate specific antigen associated with prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with Bristol-Myers Squibb Company; Amgen Inc.; Sellas Life Science Group; Merck & Co., Inc.; MedImmune/AstraZeneca PLC; Especificos Stendhal SA de CV; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ADXS
Previous Symbol
CUSIPN/A
Phone609-452-9813
Debt
Debt-to-Equity RatioN/A
Current Ratio3.95
Quick Ratio3.95
Price-To-Earnings
Trailing P/E Ratio-0.19
Forward P/E Ratio-0.41
P/E GrowthN/A
Sales & Book Value
Annual Sales$12.03 million
Price / Sales1.98
Cash FlowN/A
Price / CashN/A
Book Value$1.32 per share
Price / Book0.34
Profitability
EPS (Most Recent Fiscal Year)($2.31)
Net Income$-93,430,000.00
Net Margins-1,062.68%
Return on Equity-165.23%
Return on Assets-91.46%
Miscellaneous
Employees108
Outstanding Shares52,830,000
Market Cap$26.25 million
OptionableOptionable
Advaxis (NASDAQ:ADXS) Frequently Asked Questions
What is Advaxis' stock symbol?
Advaxis trades on the NASDAQ under the ticker symbol "ADXS."
How were Advaxis' earnings last quarter?
Advaxis, Inc. (NASDAQ:ADXS) issued its quarterly earnings results on Monday, September, 10th. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.02. The biotechnology company had revenue of $1.13 million for the quarter, compared to analysts' expectations of $1.85 million. Advaxis had a negative return on equity of 165.23% and a negative net margin of 1,062.68%. View Advaxis' Earnings History.
When is Advaxis' next earnings date?
What price target have analysts set for ADXS?
3 equities research analysts have issued 12-month price objectives for Advaxis' stock. Their predictions range from $2.00 to $5.00. On average, they expect Advaxis' stock price to reach $3.00 in the next year. This suggests a possible upside of 566.7% from the stock's current price. View Analyst Price Targets for Advaxis.
What is the consensus analysts' recommendation for Advaxis?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advaxis in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Advaxis.
Has Advaxis been receiving favorable news coverage?
Media coverage about ADXS stock has trended negative this week, InfoTrie reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Advaxis earned a media sentiment score of -2.4 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next few days.
Who are some of Advaxis' key competitors?
Some companies that are related to Advaxis include Aridis Pharmaceuticals (ARDS), Vernalis (VNLPY), Tetraphase Pharmaceuticals (TTPH), Cumberland Pharmaceuticals (CPIX), CTI BioPharma (CTIC), Synergy Pharmaceuticals (SGYP), Chiasma (CHMA), Provention Bio (PRVB), Zynerba Pharmaceuticals (ZYNE), Evofem Biosciences (EVFM), BioXcel Therapeutics (BTAI), BELLUS Health (BLUSF), Axsome Therapeutics (AXSM), Pharmaxis (PXSLY) and Entasis Therapeutics (ETTX).
Who are Advaxis' key executives?
Advaxis' management team includes the folowing people:
- Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 58)
- Mr. Anthony A. Lombardo, Exec. Officer (Age 69)
- Mr. Kenneth A. Berlin, Pres, CEO and Director (Age 54)
- Ms. Molly Henderson CPA, MBA, Exec. VP & CFO (Age 47)
- Mr. Mayo Pujols, Sr. VP of Technical Operations
Who are Advaxis' major shareholders?
Advaxis' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (2.26%). Company insiders that own Advaxis stock include Adage Capital Partners Gp, LL, Anthony A Lombardo, Robert Petit, Roni Appel, Sara Bonstein and Thomas J Mckearn. View Institutional Ownership Trends for Advaxis.
Which major investors are buying Advaxis stock?
How do I buy shares of Advaxis?
Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Advaxis' stock price today?
One share of ADXS stock can currently be purchased for approximately $0.45.
How big of a company is Advaxis?
Advaxis has a market capitalization of $26.25 million and generates $12.03 million in revenue each year. The biotechnology company earns $-93,430,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. Advaxis employs 108 workers across the globe.
What is Advaxis' official website?
How can I contact Advaxis?
Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]
MarketBeat Community Rating for Advaxis (NASDAQ ADXS)
MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe ADXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
